Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.

ABSTRACT:

Objective

To evaluate the safety and efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) in a large North American cohort.

Methods

Patients with GCA treated with TCZ between January 1, 2010, and May 15, 2020, were retrospectively identified. Kaplan-Meier methods were used to estimate time to TCZ discontinuation and time to first relapse after TCZ discontinuation. Poisson regression models were used to compare annualized relapse rates before, during, and after TCZ use. Age- and sex-adjusted risk factors associated with relapse on and off TCZ and development of adverse events of significant interest (AESIs) were examined using Cox models.

Results

One hundred fourteen patients (60.5% female) were included with mean (SD) age 70.4 (8.2) years. Median duration from

SUBMITTER: Samec MJ 

PROVIDER: S-EPMC10543396 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature